TFF Pharmaceuticals
OverviewSuggest Edit
TFF Pharmaceuticals is a biopharmaceutical company focused on developing drug products based on the Thin Film Freezing (TFF) technology platform. It develops inhalation drug products to treat chronic respiratory diseases and lung conditions. The company generates dry powder inhaler version of drugs.
| Type | Public | |
| Founded | 2018 | |
| HQ | Austin, TX, US | Map |
| Website | tffpharma.com |
Recent NewsAll News
- TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)
- TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022
- TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder
- TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures
Key People/Management at TFF Pharmaceuticals
Brian Windsor
Director & CSO
Glenn Mattes
President, Chief Executive Officer and Director
Kirk Coleman
Chief Financial Officer
Aaron Fletcher
Chairman of the Board
Stephen Rocamboli
Director
Robert S. Mills
Director
TFF Pharmaceuticals Office Locations
TFF Pharmaceuticals has an office in Austin
Austin, TX, US (HQ)
2600 Vía Fortuna #360
TFF Pharmaceuticals Financials and Metrics
TFF Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (FY, 2020) | (18.6m) |
EBIT (FY, 2020) | (18.7m) |
Market capitalization (6-May-2022) | 114.2m |
Closing stock price (6-May-2022) | 4.5 |
Cash (31-Dec-2020) | 35.3m |
TFF Pharmaceuticals's current market capitalization is $114.2 m.
Annual
Annual
Quarterly
TFF Pharmaceuticals Cybersecurity Score
TFF Pharmaceuticals Online and Social Media Presence
TFF Pharmaceuticals's Trends
TFF Pharmaceuticals News and Updates
May 02, 2022
TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)
Thin Film Freezing Technology Co-Inventor Dr. Robert O. Williams III to Deliver Platform Presentation of Data on Stabilizing and Delivering Antivirals, Antibodies and Vaccines using Thin Film Freezing Technology in the Fight Against COVID-19
April 29, 2022
TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022
Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET
April 19, 2022
TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder
Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts
March 17, 2022
TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures
New collaboration to study the use of Thin Film Freezing technology to formulate dry powder recombinant vaccine against SARS-CoV-2 for pulmonary delivery New collaboration to study the use of Thin Film Freezing technology to formulate dry powder recombinant vaccine against SARS-CoV-2 for pulmonary d…
March 11, 2022
TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference
AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Preside…
March 01, 2022
TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement
AUSTIN, Texas and SOMERSET, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the applicat…
TFF Pharmaceuticals Blogs
May 20, 2022
TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference
FORT WORTH, Texas , May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals , Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that
May 11, 2022
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Content Import
Wed, 05/11/2022 - 16:01
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 at 4:01 PM EDT
Earni…
March 24, 2022
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Content Import
Thu, 03/24/2022 - 16:27
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 24, 2022 at …
March 09, 2022
TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022
Company conference call and webcast at 4:30 PM ET AUSTIN, Texas , March 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals , Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing
November 05, 2021
TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021
Company conference call and webcast at 4:30 PM ET AUSTIN, Texas , Nov. 05, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF)
August 12, 2021
TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
Content Import
Thu, 08/12/2021 - 16:01
TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021 at 4:01 PM EDT
…
TFF Pharmaceuticals Frequently Asked Questions
When was TFF Pharmaceuticals founded?
TFF Pharmaceuticals was founded in 2018.
Who are TFF Pharmaceuticals key executives?
TFF Pharmaceuticals's key executives are Brian Windsor, Glenn Mattes and Kirk Coleman.
How many employees does TFF Pharmaceuticals have?
TFF Pharmaceuticals has 4 employees.
Who are TFF Pharmaceuticals competitors?
Competitors of TFF Pharmaceuticals include Nuvaira, Gentex Pharma and Lung Therapeutics.
Where is TFF Pharmaceuticals headquarters?
TFF Pharmaceuticals headquarters is located at 2600 Vía Fortuna #360, Austin.
Where are TFF Pharmaceuticals offices?
TFF Pharmaceuticals has an office in Austin.
How many offices does TFF Pharmaceuticals have?
TFF Pharmaceuticals has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies